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Thrombocytopenia is a common side effect of linezolid, an oxazolidinone antibiotic often used to treat multidrug-resistant
Gram-positive bacterial infections. Various risk factors have been suggested, including linezolid dose and duration of therapy,
baseline platelet counts, and renal dysfunction; still, the mechanisms behind this potentially treatment-limiting toxicity are
largely unknown. A clinical study was conducted to investigate the relationship between linezolid pharmacokinetics and toxico-
dynamics and inform strategies to prevent andmanage linezolid-associated toxicity. Forty-one patients received 42 separate
treatment courses of linezolid (600 mg every 12 h). A newmechanism-based, population pharmacokinetic/toxicodynamic model
was developed to describe the time course of plasma linezolid concentrations and platelets. A linezolid concentration of 8.06 mg/
liter (101% between-patient variability) inhibited the synthesis of platelet precursor cells by 50%. Simulations predicted treat-
ment durations of 5 and 7 days to carry a substantially lower risk than 10- to 28-day therapy for platelet nadirs of<100109/
liter. The risk for toxicity did not differ noticeably between 14 and 28 days of therapy and was significantly higher for patients
with lower baseline platelet counts. Due to the increased risk of toxicity after longer durations of linezolid therapy and large be-
tween-patient variability, close monitoring of patients for development of toxicity is important. Dose individualization based on
plasma linezolid concentration profiles and platelet counts should be considered to minimize linezolid-associated thrombocyto-
penia. Overall, oxazolidinone therapy over 5 to 7 days even at relatively high doses was predicted to be as safe as 10-day therapy
of 600 mg linezolid every 12 h.
The oxazolidinone linezolid remains an important antimicro-bial agent against multidrug-resistant Gram-positive patho-
gens. Linezolid was originally approved for up to a 28-day dura-
tion of therapy to treat indicated infections, such as skin and skin
structure infections, community-acquired and nosocomial pneu-
monia, and vancomycin-resistant Enterococcus faecium (1). Still,
linezolid has been and continues to be used for longer treatment
durations (2), an approach facilitated by favorable pharmacoki-
netic (PK) properties, such as close to 100% oral bioavailability (3,
4). Linezolid treatment is associated with reversible thrombocyto-
penia, particularly when used for14 days (2, 5–7). Patients with
baseline platelet counts of 241  109/liter or less (8) and renal
insufficiency (9) are at particular risk for linezolid-induced
thrombocytopenia. In this context, implementing systematic
monitoring programs (10) and predicting and minimizing the
extent of platelet decline in high-risk patients is important.
Evidence for a relationship between linezolid exposure and
thrombocytopenia exists. Data from highly debilitated, critically
ill compassionate-use patients were used to develop a model re-
lating changes in platelet counts to linezolid exposure, treatment
duration, and baseline platelet counts (11). A population model
has recently been developed based on data obtained in 45 Japanese
patients to quantitatively describe the relationship between lin-
ezolid exposure and platelet counts (12). In the present paper, we
greatly extended the exposure-response relationship established
by Forrest et al. (11) and performed an in-depth mechanism-
based modeling analysis of the time course and potential mecha-
nisms of the toxicodynamics of linezolid. This allowed us to pre-
dict the time course of platelet counts for linezolid dosage
regimens with different dose levels, durations of therapy, and
changes in dose intensity over time.
The mechanism(s) responsible for linezolid-induced throm-
bocytopenia have not been clearly delineated. Classical myelosup-
pression has been implicated, in which direct toxicity to bone
marrow or hematopoietic cells is observed (13). Some case reports
support a drug-induced immune-mediated mechanism, based on
observations that include the presence of megakaryocytes or drug-
related antiplatelet antibodies and the abrupt onset of platelet de-
cline following initiation of linezolid therapy (14, 15). Sasaki et al.
depicted linezolid-induced thrombocytopenia in their model as
the inhibition of the proliferation of progenitor cells (12).
The current study aimed to characterize the relationship be-
tween linezolid concentrations and thrombocytopenia over time
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and to predict the time course and extent of toxicity for standard
and innovative linezolid dosage regimens. These analyses helped
guide strategies to predict and manage this toxicity. We utilized
mechanism-based population pharmacokinetic/toxicodynamic
(PK/TD) modeling and explored risk factors for the development
of linezolid-induced thrombocytopenia.
(These data were presented in part at the 46th Interscience
Conference on Antimicrobial Agents and Chemotherapy, San
Francisco, CA, 27 to 30 September 2006.)
MATERIALS AND METHODS
Design and patient population. This study was a prospective, open-la-
beled, observational study of patients receiving linezolid treatment at
three hospitals: the Departments of Infectious Diseases at the Alfred and
Austin Hospitals, Melbourne, Victoria, Australia, and the Transplant Unit
of the University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA,
USA. The study protocol was approved by the relevant ethics committees/
institutional review boards at the hospitals and Monash University and
was carried out in accordance with the revised version of the Declaration
of Helsinki.
Patients were enrolled within the 28-month period between October
2004 and January 2007. Males or nonpregnant females of at least 18 years
of age initiated on linezolid therapy by their treating physician were in-
cluded in the study. Patient medical history, demographic data, previous
and concomitant medication, and linezolid dosage details were collected.
Hematological parameters (including platelet and hemoglobin values)
were measured up to 5 days before the start of linezolid therapy and
collected at least weekly during treatment. Details on potential contribu-
tors to thrombocytopenia (e.g., preexisting conditions, concomitant
drugs, bleeding events, and blood products) were collected before and
during linezolid therapy.
Drug administration and PK sample collection. Patients received
600 mg intravenous or oral linezolid twice daily for at least 4 days; some
patients received both intravenous and oral therapy but not simultane-
ously. Blood samples were drawn at time points in relation to one lin-
ezolid dose (predose and 2, 4, and 8 h postdose) in all but one patient,
whose samples were collected around two consecutive linezolid doses to
generate peak and trough concentrations. Where possible, the PK samples
were collected within the first week of therapy to precede any drug-in-
duced hematological toxicity. Blood samples were drawn into 10 ml
K3EDTA Vacutainer tubes (Becton, Dickinson, Franklin Lakes, NJ, USA)
and centrifuged to harvest plasma for immediate freezing and storage at
20°C. Plasma linezolid concentrations were measured using a validated
high-performance liquid chromatography (HPLC) method (16).
Population pharmacokinetic model structure. Pharmacokinetic
models with one or two disposition compartments and first-order ab-
sorption were evaluated. To describe an absorption delay, models with or
without up to 10 serial absorption-lag compartments were assessed. Elim-
ination was described by a first-order (linear), mixed-order (Michaelis-
Menten), or parallel first-order and mixed-order process. Additionally, an
inhibition compartment approach was considered to describe a time-
dependent saturation of linezolid clearance (17–19). Oral bioavailability
was initially estimated and eventually fixed at 100% (4).
The differential equations used to describe the amount of drug in the
absorption lag compartments (Fig. 1, Lag 1, Lag 2, and Lag 3), gut com-
partment, and central compartment (A1) were as follows (initial condi-
tion [IC] for all, 0):
dLag1
dt
klag · Lag1 (1)
dLag2
dt
 klag · Lag1 Lag2 (2)
dLag3
dt
 klag · Lag2 Lag3 (3)
dGut
dt
 klag · Lag3 ka · Gut (4)
dA1
dt
 ka · Gut RInfusion CL · C1 (5)
The klag is the rate constant describing the absorption lag phase, ka is
FIG 1 Structure of the final mechanism-based population pharmacokinetic/toxicodynamic model. The pharmacokinetic model is comprised of three absorp-
tion lag compartments, a gut compartment, and a central compartment. One series of 15 transit compartments was used to describe platelet precursor cells in the
bone marrow, and another series of 15 transit compartments to describe platelets in the circulating pool. Platelets displayed a feedback effect on the synthesis of
platelet precursor cells. A lack of platelets in the circulating pool compared to the platelet count at steady state caused a stimulation of platelet precursor synthesis,
and an excess of platelets in the circulating pool caused an inhibition of platelet precursor synthesis.
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the absorption rate constant, RInfusion is the rate of infusion, C1 is the drug
concentration in the central compartment, and CL is total clearance.
The area under the plasma concentration-time curve over 24 h
(AUC24), averaged over days 1 to 7 of treatment, was calculated by nu-
merical integration of the individually fitted concentration profiles. For
patients receiving linezolid for less than 7 days, the average AUC24 was
calculated over the reduced treatment period. The average AUC24 was
used because dosing times changed slightly during therapy in some pa-
tients.
Mechanism-based population pharmacokinetic/toxicodynamic
model. The effect of linezolid treatment on platelet counts was examined.
A transit compartment approach (20) was employed to describe the life
span of platelet precursor cells and platelets. Turnover models with 1, 3, 6,
9, 12, or 15 compartments each for platelet precursor cells (Pre1 to Pre15)
and platelets (PL1 to PL15) were considered to describe different profiles of
the life span distribution for platelets (21–23). The existence of a larger
number of compartments for a specific cell type results in a narrower
distribution of platelet life spans for a given patient.
Different possible mechanisms of linezolid-induced thrombocytope-
nia have been described (13–15). In the current investigation, linezolid
was assumed to inhibit the synthesis of platelet precursor cells (mecha-
nism 1 [Fig. 1]), kill platelet precursor cells (mechanism 2), kill platelets
(mechanism 3), or stimulate the natural loss rate constant of platelets
(kout) (mechanism 4). Mechanism 2 involved linezolid stimulating a loss
of platelet precursor cells from compartments Pre1 to Pre15, and mecha-
nism 3 a loss of platelets from compartments PL1 to PL15 (Fig. 1). Mech-
anisms 2 and 3 could be explained by an immune-mediated elimination
(14) and were implemented using a saturable, Hill-type loss function.
Based on the results from Sasaki et al. (12) a homeostatic feedback
mechanism was implemented, contributing to a temporary increase in
platelet counts above the baseline after cessation of linezolid therapy. Our
models considered that a decline of platelets below the patient-specific
platelet baseline either stimulated the synthesis (Kin) of platelet precursors
or enhanced the transfer rate constant (ktr) of platelet precursors. The
latter process was assumed to result in a shorter maturation time of plate-
let precursor cells.
For the model with mechanism 1, the decline of platelet counts was
modeled through inhibition of platelet precursor synthesis by linezolid
(Fig. 1). The inhibitory function incorporated parameters for the maxi-
mal extent of inhibition (Imax) and the concentration achieving 50% of
Imax (IC50) to inhibit the synthesis (Kin) of the first platelet precursor
compartment, as follows (IC, FIni,Pre · BasePre):
dPre1
dt
 1 Imax · C1IC50 C1 · StimFeedback · Kin ktr · Pre1 (6)
Kin is the zero-order rate of precursor synthesis, ktr the first-order rate
constant for transfer of platelet precursor cells, and BasePre the steady-
state value for platelet precursors in the absence of drug, calculated as
BasePre BasePL · kout/ktr. The BasePL is the baseline of platelets at steady
state (i.e., without drug), and kout the first-order rate constant for transfer
of platelets. To account for a deviation of platelet precursor cells from
their steady-state value at time zero, the factor FIni,Pre was included. This
factor accounts for patients who are not at the baseline of platelet precur-
sor cells and platelets. The inclusion of the factors FIni,Pre and FIni,PL (see
below) allowed the model to describe profiles with increasing or decreas-
ing platelet counts during the first days of linezolid therapy.
The stimulation factor (StimFeedback) in equation 6 affected the syn-
thesis of platelet precursor cells based on a function of the ratio of the
baseline of the platelet count at steady state (BasePL) and the current
concentration of platelets in the circulation (PL; see below). The exponent
() was included to describe the extent of feedback, as described previ-
ously (12, 24). For a positive  value, StimFeedback is larger than 1 and
therefore stimulates the synthesis of platelet precursors if PL decreases
below BasePL.
StimFeedback BasePLPL  (7)
If platelet counts increase above their steady-state value, the synthesis
of platelet precursor cells is partially inhibited (StimFeedback 1 if  0).
Newly generated platelet precursor cells (Pre1) had to undergo transition
through 15 transit compartments, reflecting their maturation time. The
differential equation for the second to fifteenth (i  2 to 15) platelet
precursor compartments was as follows (IC, FIni,Pre · BasePre):
dPrei
dt
 ktr · Prei1 Prei (8)
The differential equations for the 15 platelet compartments were as
follows (IC for both equations, FIni,PL · BasePL; j 2 to 15):
dPL1
dt
 ktr · Pre15 kout · PL1 (9)
dPLj
dt
 kout · PLj1 PLj (10)
To account for platelets not being at steady state at time zero, FIni,PL
was included as a factor with a fixed mean of 1 and an estimated between-
subject variability (BSV) similar to FIni,Pre for precursor cells (see equation
6). The output equation for the platelet count in the circulation (PL) was
the average of the 15 platelet compartments, as follows:
PL
1
15
· 
1
15
PLj (11)
Parameter variability and residual error model. The BSV was de-
scribed by a log-normal distribution for all parameters (except Imax, which
was modeled using a logistic transformation). Residual error was de-
scribed by an additive plus proportional model for linezolid concentra-
tions and platelets, as described previously (25, 26).
Covariate effect model. Body size was described by weight (WT),
representing the lower value of ideal body weight (IBW) (27) and total
body weight. A standard WT (WTSTD) of 65 kg was applied. The glomer-
ular filtration rate (GFR) was estimated using the Cockcroft and Gault
formula (28) for a patient with normal body size (WTSTD 65 kg) as de-
scribed previously (29, 30). GFRi for the ith patient with a nominal weight
of 65 kg (age is in years, FSex is 0.85 for females and 1 for males, and SCR
is the serum creatinine concentration in mg/dl) was calculated as follows:
GFRi
140 agei
SCRi
·
65
72
· FSex,i (12)
The GFR was included as a time-dependent covariate; renal function
(RF) was assumed to be linearly related to GFR and calculated by normal-
izing GFRi to a standard GFR of 120 ml/min with RFi  GFRi/GFRSTD.
The assumption on the correlation of renal function and creatinine clear-
ance enabled the estimation of renal (CLR) and nonrenal clearance
(CLNR) in the absence of urine data, as follows:
CL FSize,CL · RFi · CLR CLNR (13)
FSize,CL is the allometric size factor for clearance using an allometric
exponent of 0.75, and FSize,V is the allometric scale factor for volume of
distribution with a fixed exponent of 1 and a reference WT of 65 kg
(31).
Estimation. All parameters of the population PK/TD model were si-
multaneously estimated using the importance sampling algorithm
(pmethod 4) in parallelized S-ADAPT (version 1.57) via the SADAPT-
TRAN facilitator (25, 26). Models were compared using the objective
function (1 · log-likelihood in S-ADAPT), plausibility of parameter es-
timates, standard diagnostic plots, visual predictive checks (VPCs) (32),
and normalized prediction distribution error (NPDE) (33). Noncom-
partmental analysis using WinNonlin Pro (version 5.3) was performed to
generate AUC24 values for the individual fitted concentration-time pro-
files that were predicted at 1,000 time points for each patient.
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Simulations of platelet time courses for various linezolid dosage
regimens. Monte Carlo simulations in 1,000 patients over 8 weeks (in-
cluding 4 weeks of treatment and 4 weeks of recovery) for different oral
dosage regimens were performed using Berkeley Madonna (version
8.3.18) to simulate the probability of reaching a nadir platelet count below
100  109/liter (threshold for clinically significant thrombocytopenia).
The durations of therapy considered were 5, 7, 10, 14, and 28 days. The
simulated patient population had a mean WT of 65 kg (coefficient of
variation [CV], 18%) and a uniform distribution for creatinine clearance
ranging from 15 to 125 ml/min. Simulations were performed for mean
baseline platelet counts of 150, 250, and 400 109/liter. To consider small
deviations of platelet and platelet precursor counts at initiation of therapy
from baseline, the factors FIni,Pre and FIni,PL were applied in conjunction
with their respective estimated BSV values.
Statistical analysis. Univariate analysis was carried out to identify risk
factors for the development of thrombocytopenia (defined as a platelet
count of 100  109/liter). The variables evaluated (where available)
included sex, age, weight, body mass index (BMI), baseline creatinine
clearance, duration of linezolid administration, AUC24 during the first 7
days, Charlson’s age-comorbidity score (34), comorbidities (diabetes,
anemia, peripheral vascular disease, chronic obstructive pulmonary dis-
ease, liver disease, malignancy, gastrointentinal bleeding, and coagulopa-
thy) and concomitant drug usage (heparin [including low-molecular-
weight heparin], blood products, immunosuppressants, blood
transfusion, and darbepoetin alpha). The Mann-Whitney test for quanti-
tative variables and Fisher’s exact test for qualitative variables were ap-
plied. The statistical program SPLUS version 8.2 was utilized for all anal-
yses (SPLUS; Tibco).
RESULTS
Patient population. A total of 41 patients (25 male and 16 female)
(Table 1) were included in the study (7 from the Alfred Hospital, 21
from the Austin Hospital, and 13 from UPMC). Patients were treated
with linezolid (600 mg every 12 h [q12h]) for a mean duration of 22
days (standard deviation [SD], 15 days; range, 5 to 54 days). A total of
42 treatment courses were evaluated, as one patient from the UPMC
was treated with linezolid on two separate occasions.
Population pharmacokinetics. A one-compartment disposi-
tion model with first-order elimination and three absorption lag
compartments was chosen as the final PK model (Fig. 1; Table 2).
The inclusion of 3 absorption lag compartments significantly im-
proved the objective function (P 0.05, likelihood ratio test) and
provided improved curve fits compared to a one-compartment
model with first-order absorption. The objective function was not
improved by inclusion of a peripheral compartment or of satura-
ble elimination, possibly due to the sparse nature of the data set
(161 linezolid concentrations from 41 patients/42 treatment
courses). The inclusion of creatinine clearance and weight as co-
variates reduced the variance in total clearance by 12% (from a CV
of 52.2% to 48.9%).
The AUC24 during up to the first 7 days had an average of 223
mg · h/liter (CV, 52%), and the median (range) was 198 (65.2 to
551) mg · h/liter. The AUC24/MIC values would have been above
100 in 90% of patients for a MIC of 1 mg/liter, in 50% of patients
for a MIC of 2 mg/liter, and in 7% of patients for a MIC of 4
mg/liter.
Platelet data. There was high BSV in the observed baseline
(mean, 288 109/liter; CV, 53.2%; range, 31.0 to 679 109/liter)
and nadir (mean, 192 109/liter; CV, 71.1%; range, 13.0 to 598
109/liter) platelet counts, as well as in the maximal percent change
of platelet counts during linezolid therapy (mean, 32.5%; CV, 102%;
range, 79.2 to 91.0%). Fourteen patients (34%) developed severe
thrombocytopenia, defined as a platelet count of 100 109/liter,
of which 4 had platelet counts of 100 109/liter at baseline. A
total of 24 (57%) patients demonstrated 30% decreases from
baseline to nadir.
Following removal of the 4 patients with baseline platelet
counts of 100  109/liter, baseline platelet count was the only
variable identified to be associated with the occurrence of throm-
bocytopenia by univariate analysis (P 0.0084) (Table 1).
Mechanism-based population PK/TD model. A delay be-
tween the initiation of linezolid therapy and the decline of platelets
in most patients suggested that a precursor indirect response
model would be more appropriate than a model without precur-
sor compartments (35, 36). Models with 1, 3, 6, 9, 12, and 15
compartments each for precursor cells and platelets were evalu-
ated. The objective function improved by a range of 4.4 to 86 with
the inclusion of transit compartments, leading to the acceptance
of a final model with 15 transit compartments each for precursor
and platelet cells (Fig. 1). The objective function of a model with
no precursors and only one platelet compartment was worse by
148 than that of the final model. The final model with 15 transit
compartments also performed better than models with fewer
transit compartments after inclusion of the feedback mechanism.
The platelet profiles for several patients suggested that platelet
counts were not at steady state before the initiation of linezolid
therapy, as shown for patients 1, 12, 28, 31, and 42 (Fig. 2). Over-
all, slightly over half of the patients showed a considerable increase
or decrease of platelet count profiles during the first few days of
TABLE 1 Univariate evaluation of risk factors for development of
thrombocytopenia
Characteristic
Value for patients who
did or did not develop
thrombocytopeniaa
P
value
Yes
(n 10)
No
(n 28)
Continuous variables [mean (CV%)]
Age (yr) 54.0 (32.6) 60.5 (25.5) 0.50
Weight (kg) 73.1 (22.3) 75.1 (18.7) 0.60
Body mass index (kg/m2) 24.4 (16.5) 26.1 (16.4) 0.37
Baseline platelet count (109/liter) 214 (37.2) 347 (41.2) 0.0084
Baseline creatinine clearance
(ml/min/65 kg) (28)
68.3 (49.9) 71.2 (56.2) 1.00
Baseline serum albumin (g/liter) 31.1 (21.6) 26.5 (26.3) 0.075
Duration of linezolid treatment (days) 28.3 (63.7) 20.3 (62.1) 0.15
AUC24h (mg · h/liter) 243 (50.3) 213 (54.0) 0.38
Charlson’s age-comorbidity score (34) 4.70 (48.4) 5.14 (45.4) 0.43
Categorical variables [count (% within
group)]
Female 4 (40) 12 (43) 1.00
Diabetes 5 (50) 7 (25) 0.26
Anemiab 6 (60) 2 (7.1) 0.47
Peripheral vascular diseaseb 5 (50) 8 (29) 0.26
Liver diseaseb 3 (30) 8 (29) 1.00
Heparin 4 (40) 17 (61) 0.29
Blood transfusion 7 (70) 13 (46) 0.28
Immunosuppressants 5 (50) 9 (33) 0.45
Darbepoetin alpha 3 (30) 5 (18) 0.41
a Thrombocytopenia was defined as a platelet count of100 109/liter. Individuals
with baseline counts of100 109/liter were removed (n 4).
b Baseline comorbidity.
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therapy. This clearly suggested that the inclusion of FIni,Pre and
FIni,PL in the model was beneficial. Consistent with this, inclusion
of the factors FIni,Pre (estimated CV, 21.5%) and FIni,PL (CV,
23.6%) improved the objective function by 76 (P 0.001) (Table
2). These CVs suggested considerable deviations of the baseline
precursor and baseline platelet counts from their steady-state
value, which was considered in the Monte Carlo simulations.
Initially, models without a feedback mechanism were assessed.
Inhibition of platelet precursor synthesis (mechanism 1) and di-
rect killing of platelet precursor cells (mechanism 2) by linezolid
yielded similar objective functions, whereas models with direct
killing of platelets (mechanism 3) or stimulation of natural loss of
platelets (kout; mechanism 4) resulted in worsening of the objec-
tive functions by approximately 50 compared to models with
mechanisms 1 and 2. For this reason, mechanisms 1 and 2 were
chosen for further investigation as potential mechanisms of lin-
ezolid-induced thrombocytopenia.
Inclusion of the feedback mechanism affecting the synthesis of
precursor cells improved the objective function by 99 (P 0.001)
for a model depicting inhibition of precursor synthesis (mecha-
nism 1). A smaller improvement of 49 (P 0.001) was seen after
inclusion of feedback for the model with mechanism 2. Specifying
the feedback as an accelerated transfer (ktr) for platelet precursors
did not significantly improve the objective function. Due to the
best objective function for the model with mechanism 1, inhibi-
tion of precursor synthesis by linezolid and a feedback affecting
the synthesis of precursor cells was chosen as the final model (Fig.
1). Inclusion of direct killing of platelets (mechanism 3) in addi-
tion to inhibition of synthesis of platelet precursors by linezolid
(mechanism 1) yielded no improvement and a very slow maximal
killing half-life of 35 days. Therefore, the final model included
mechanism 1 but not mechanism 3.
The final PK/TD model yielded good individual curve fits for
the complex time course of platelet counts (Fig. 2), including a
lack of steady state at time zero and feedback. The IC50 was esti-
mated as 8.06 mg/liter and had a large BSV with a CV of 101%
(Table 2). Individual curve fits were precise and unbiased for
plasma linezolid concentrations (slope, 1.04; r, 0.95) and platelets
(slope, 1.01; r, 0.98) (Fig. 3). The population fits were reasonably
unbiased and precise for plasma concentrations (slope, 1.10; r,
0.56). As expected, due to the large BSV in observed baseline plate-
let counts (observed CV of 52%), the population fits for platelets
demonstrated no strong relationship (Fig. 3). After adjusting the
population fits for the individual observed baseline platelet count,
a moderate relationship emerged (slope, 1.08; r, 0.76) (Fig. 3). The
NPDE plots for plasma concentrations (results not shown) and
platelets (Fig. 3) were unbiased and reasonably mirrored a stan-
dard normal distribution.
The final mechanism-based model contained five estimated
PK parameters and seven estimated PD parameters. The relative
standard errors (SE%) were small (20%) for all but two popu-
lation means and slightly larger for these two parameters (Table
2). As expected, the SE% for the between-subject variability esti-
mates were larger for our data set containing 42 plasma linezolid
concentration and platelet profiles.
Simulation results. The predicted probability for nadir plate-
let counts below 100 109/liter was lowest for durations of ther-
apy of 5 and 7 days and was substantially higher for 10, 14, and 28
days of therapy (Fig. 4). For a patient group with a simulated
average baseline of 250 109/liter, 600 mg linezolid q12h for 10 or
14 days yielded noticeably higher toxicity than linezolid dosage
regimens of 400 mg q12h or 600 mg q24h (Fig. 4A). In this patient
group, front loading of 1,200 mg q12h or of 2,400 mg q12h yielded
levels of toxicity similar to those yielded by 600 mg q12h, if the
TABLE 2 Parameter estimates of the mechanism-based population pharmacokinetic/toxicodynamic model
Parameter Symbol Unit
Population
mean (SE%)
BSVa
(SE%)
Mean absorption lag time Tlag
b Min 69.2 (16) 0.600 (47)
Absorption half-life Tabs1/2
b Min 10.3 (6.3) 0.147 (83)
Total clearance CLc Liter/h 6.72 0.489 (24)
Nonrenal clearance CLNR
c Liter/h 4.55 (18)
Renal clearance CLR
c Liter/h 2.17 (58)
Volume of distribution Vc Liter 44.3 (5.8) 0.036 (106)
Baseline of platelets BasePL 10
9/liter 252 (10) 0.651 (24)
Initial condition divided by individual steady-state estimate for platelet precursors FIni,Pre 1 (fixed)
d 0.215d (43)
Initial condition divided by individual steady-state estimate for platelets FIni,PL 1 (fixed)
d 0.236d (37)
Plasma linezolid concn resulting in 50% of maximal toxicity (Imax fixed to 1.0) IC50
e mg/liter 8.06e (35) 1.01 (60)
Mean life span of precursor cells MTTPre
f Days 7.68 (11) 0.347 (34)
Mean life span of platelets MTTPL
f Days 6.80 (13) 0.203 (66)
Gamma, describing the extent of feedback  1.02 (11) 0.15 (fixed)
Standard deviation of the additive residual error for plasma linezolid concentrations SDin mg/liter 0.309 (56)
Proportional residual error for plasma linezolid concentrations SDsl 0.225 (15)
Standard deviation of the additive residual error for platelets PDin 10
9/liter 15.1 (19)
Proportional residual error for platelets PDsl 0.0755 (17)
a Between-subject variability (BSV) is expressed as the apparent coefficient of variation (i.e., the square root of the estimated variance). The estimate in parentheses (SE%)
represents the relative standard error (i.e., the uncertainty of the estimate).
b klag was calculated as 3/Tlag and ka as Ln(2)/Tabs1/2.
c Estimates for patients with a standard weight of 65 kg (as defined in the method section) and a standard creatinine clearance of 120 ml/min. If the volume of distribution and
clearances were scaled using a standard body weight of 70 kg instead of 65 kg, the reported volume of distribution would be 7.69% and all clearances would be 5.72% higher than
the values reported herein.
d The population means for FIni,Pre and FIni,PL were fixed to 1, and the associated BSV terms were estimated.
e A Hill coefficient and Imax were estimated, and both were close to 1.0 and eventually fixed to 1.0 for the final model. This choice had a minimal impact on the objective function.
f MTT, mean transit time. ktr was calculated as 15/MTTPre and kout as 15/MTTPL.
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front loading was constrained to two dosing intervals over the first
day of therapy (Fig. 4B).
As expected for a population with a mean baseline platelet
count of 150 109/liter, significantly more toxicity was predicted
for all regimens (Fig. 4C). Considerably less toxicity was predicted
for a patient population with a mean baseline of 400 109/liter. At
this higher baseline, front loading of 1,200 mg q12h for 5 days
followed by 300 mg or 600 mg q12h yielded a toxicity comparable
to that of the standard 600 mg q12h regimen (Fig. 4D).
DISCUSSION
The relationship between linezolid PK and TD was first examined
in a study of a highly debilitated, critically ill compassionate-use
population (10, 37, 38) and was further investigated in this study
with a patient population more typical of postapproval usage pat-
terns. Mechanism-based modeling was performed to explore po-
tential mechanisms of linezolid toxicity and to describe and pre-
dict platelet counts over time for standard and PD-optimized
linezolid dosage regimens with different durations of therapy. The
modeling analysis by Sasaki et al. (12) for Japanese patients re-
ported a considerably increased risk of toxicity for common lin-
ezolid dosage regimens in patients with impaired renal function or
severe liver cirrhosis.
In the current study, patients were treated with linezolid for a
wide range of infecting organisms, infection types, and therapy
durations (5 to 54 days; mean, 22 days). Treatment extended be-
FIG 2 Observed (dots) and individual fitted (lines) plasma linezolid concentrations and platelet counts for a representative selection of patients. Note that the
platelet profiles for patients 12, 28, and 31 were rising during the first week and therefore did not start at steady state.
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yond the maximum recommended duration of 28 days in eight
patients (1). The high BSV in PK in the current study was consis-
tent with that reported in other patient populations (18, 37) and
has both potential efficacy and toxicity implications. The popula-
tion pharmacodynamic model for the compassionate-use popu-
lation (38) linked AUC/MIC values of 100 to clinical cure and
bacterial eradication endpoints. In the present study, 50% of pa-
tients would have failed to reach the reported target AUC/MIC
exposure of 100 (38) based on a MIC90 of 2 mg/liter for linezolid
(39).
A one-compartment population PK model with first-order
elimination and an oral absorption lag best described the current
data. Our final PK model was linear and thus differed from that for
the compassionate-use population data, which included parallel
linear renal clearance and Michaelis-Menten nonrenal clearance
pathways (37). The sparsely sampled plasma linezolid concentra-
tions and relatively small sample size of the current study poten-
tially contributed to these differences. In agreement with the
model by Meagher et al. (37), creatinine clearance explained some
of the variability of total clearance.
Approximately one third of patients in the current study de-
veloped thrombocytopenia, defined as platelet counts of less than
100 109/liter, consistent with reports on postapproval use (6, 7,
12). Baseline platelet count was the only variable significantly as-
sociated with the occurrence of thrombocytopenia based on uni-
variate analysis. The small number of observed associations lim-
ited further exploration of risk factors via multivariate analysis.
This was potentially caused by our relatively small sample size and
other clinical factors in our patient group.
Several previously proposed mechanisms for linezolid-in-
duced thrombocytopenia (13–15) were used to guide our model-
ing analysis. Sasaki et al. (12) described the toxicity of linezolid on
platelets by a mechanism-based model with one progenitor pool
compartment, three transit compartments, and one compartment
for circulating platelets. This model was originally developed for
the effect of anticancer drugs on neutrophils and leukocytes (24)
and assumes a linear inhibition of synthesis of progenitor cells and
a monoexponential function (i.e., one compartment) for circulat-
ing platelets.
As shown by prior studies (22, 23), the life span distribution of
circulating platelets is, however, complex and, as such, not likely
to be well described by either a monoexponential process or a
single life span for all platelets. Therefore, we evaluated different
shapes for the life span distribution for platelets and precursor
cells by exploring models with different numbers of transit com-
partments. As indicated by the final model with 15 transit com-
partments, the modeled distribution of life spans for platelets
and platelet precursor cells was narrower than that predicted by
a monoexponential function discussed previously (20, 40). The
estimated mean transit times of 7.68 days (CV, 34.7%) for pre-
cursor cells and 6.80 days (20.3%) for platelets (Table 2) were
in excellent agreement with estimates in the literature for the
maturation (approximately 9 days) and life span of platelets (5
to 10 days) (21–23).
FIG 3 Observations versus individual (left) and population-fitted (middle) plots for linezolid concentrations in plasma (top) and platelet counts (bottom). The
right-hand pair of plots show normalized prediction distribution errors (NPDE) for platelets and the baseline-adjusted population fit plot. For baseline
adjustment, the population-fitted profiles were multiplied by the ratio of the individual observed baseline at time zero for the respective patient and the
population mean baseline.
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The final model described the linezolid-induced thrombocyto-
penia by an inhibition of the synthesis of platelet precursor cells by
linezolid. The inclusion of a feedback mechanism with a lack of
platelets stimulating the production of platelet precursor cells
(Fig. 1) improved the model fits significantly. The estimated ex-
ponent () of 1.02 indicated a stronger feedback than was esti-
mated by Sasaki et al. (0.203) (12). To further investigate this
feedback, the model structure of Sasaki et al. was applied to the
current data set and yielded an exponent of 2.3, suggesting an even
stronger feedback than was estimated by the present model (Table
2). While the reasons for these different extents of feedback are not
fully understood, our additional analysis shows that this may be
partly attributed to the different data sets used, and feedback was
clearly beneficial.
If platelets decline below their steady-state baseline, the feed-
back upregulates the synthesis of platelet precursor cells for the
duration of linezolid therapy. Therefore, the model predicts that
the lowest platelet count usually occurs after 2 to 3 weeks of lin-
ezolid therapy, if the linezolid exposure is constant during ther-
apy. This feature was consistent with our data set (see the data for
patients 2 and 23 in Fig. 2, for example).
The proposed mechanism-based model (Fig. 1) contained 12
structural model parameters which were estimated with good pre-
cision (SE% of 20% for all but two population means). As ex-
pected, the uncertainty of the estimated BSV parameters was
larger. However, the NPDE (Fig. 3) suggested that the variability
between patients was well captured by our model and BSV param-
eter estimates. While our study only contained 42 plasma linezolid
concentration and platelet profiles, these results suggested that
our sample size and study design were adequate to support the
proposed mechanism-based model (Table 2). This is in agreement
with a previous simulation-estimation study using a much more
complex PK/PD model with 45 structural model parameters that
were simultaneously estimated based on data from 48 patients
using a sparse sampling design (26).
Our Monte Carlo simulations predicted a substantially lower
risk for nadir platelet counts of below 100 109/liter for therapy
durations of 5 to 7 days than for durations of 10 to 28 days (Fig. 4).
This prediction was in good agreement with the observed proba-
bility of thrombocytopenia in the study by Nukui et al. (41) and
with the reported higher incidence of thrombocytopenia develop-
ment after 14 days of treatment (2, 5). While the predicted prob-
ability for platelet toxicity did not differ noticeably for therapy
durations of 14 or 28 days, this prediction may be affected by a
time-dependent autoinhibition of linezolid clearance (not in-
cluded in the current model). The latter model feature was previ-
ously reported based on data from healthy volunteers (18, 42).
Overall, therapy duration was a more important predictor of tox-
icity than was linezolid dose.
As expected, a higher risk for toxicity was predicted for a low
baseline platelet count of 150 109/liter than for baseline counts
of 250  109/liter or 400  109/liter. Therefore, high-dose lin-
ezolid regimens seem not warranted for patients with low baseline
platelet counts. Front-loaded linezolid regimens have recently
demonstrated promising bactericidal activity (43, 44). Based on
the predicted toxicity for patients with normal to high baseline
platelet counts (Fig. 4), more aggressive, PD-optimized dosing of
1,200 mg linezolid q12h for up to 5 days followed by 600 (or 300)
mg q12h may have utility in patients with baseline platelet counts
of 400 109/liter or above.
In summary, baseline platelet counts and therapy durations of
10 days or longer were the most important predictors of linezolid
toxicity. Even at relatively high linezolid doses, therapy for 5 to 7
days was predicted to be substantially safer than longer treatment
FIG 4 Simulated probabilities for nadir platelet counts below 100 109/liter
for various normal and front-loaded linezolid dosage regimens when mean
baselines were as indicated.
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durations. For patients with normal and high baseline platelet
counts, innovative, PD-optimized, front-loaded dosage regimens
were predicted to be at least as safe as a standard regimen of 600
mg every 12 h. Inhibition of synthesis of platelet precursor cells
was identified as the most likely mechanism of toxicity. The mech-
anism-based model developed can be used to individualize lin-
ezolid therapy to maximize the efficacy and minimize the risk for
toxicity. In view of the demonstrated increased risk of toxicity
observed after 2 weeks of linezolid therapy and large variability in
PK and TD, close monitoring of patients for development of tox-
icity remains important.
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